This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Research Shows Survival Benefit With Daily Dialysis In A Nursing Home Setting

LAS VEGAS, April 24, 2014 /PRNewswire/ -- On Wednesday, April 23, 2014, Affiliated Dialysis Centers, LLC ("ADC") shared the release of clinical data in a Late Breaking Poster Session at the 2014 National Kidney Foundation (NKF) Spring Clinical Meetings in Las Vegas, NV. Xelay Acumen, a strategy and medical data analytics firm, independently led the data collection and analysis effort, and Dr. Alex Yang, M.D. presented the results. Earlier this year, ADC presented the first results of a large epidemiological health outcomes clinical research study involving End Stage Renal Disease (ESRD) patients who received their dialysis care on-site in the nursing home setting. The study utilized the largest known database of ESRD patients receiving dialysis in the nursing home setting, consisting of nearly 4,000 patients tracked over a 6-year follow-up period. In this new study utilizing this clinical database, health status and patient outcomes were compared in nursing home patients receiving daily home hemodialysis vs. conventional thrice weekly hemodialysis.

Patients with ESRD on dialysis have one of the highest mortality rates of any disease, surpassing many cancers. Within this ESRD patient population, nursing home patients typically have even greater health challenges by virtue of their need to be in a nursing home. Thus identifying beneficial treatment paradigms for these patients is a significant clinical priority.

The key findings from this large epidemiological research study were that, compared to conventional thrice weekly dialysis, patients treated on-site in a nursing home setting with daily home hemodialysis had:
  1. Generally improved health status
  2. Lower monthly mortality rates
  3. Significantly longer median survival (50 months vs 30 months; P<0.001) 

"The ADC database is a unique and extremely important research tool, which allows us to study a large population of ESRD patients on dialysis in the nursing home setting and test hypotheses about optimal care and outcomes for this at-risk patient population," said Dr. Yang.  "The improvements in health status, and particularly in overall survival, in patients treated with daily home dialysis in this study are provocative and suggest the need for a prospective outcomes study."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs